Company profile

Virometix

Virometix develops a new generation of vaccines using its Synthetic Virus-Like Particle (SVLP) technology, which enables the creation of a novel type of synthetic nanoparticles. Similarly to real viruses, SVLPs can generate a strong and long-lasting immune response. However, unlike real viruses, SVLPs are made entirely by chemical synthesis with associated advantages in stability, safety, production and quality control, and are completely modular. This enables the design of tailored vaccines for the prevention and treatment of a broad range of infectious and chronic human diseases. Virometix is developing several vaccines including one against streptococcal diseases.

More news about Virometix

11.01.2021 09:53

New leaders on the executive floor

Please login or
register to use the
awards follow feature
23.07.2020 08:45

Biotech startup Virometix obtains CHF 7.5 M in a series B round

Please login or
register to use the
awards follow feature
04.02.2019 12:10

Anna Sumeray takes the lead at Virometix

Please login or
register to use the
awards follow feature
04.09.2017 11:45

Virometix closes extension financing round

Please login or
register to use the
awards follow feature
22.05.2017 08:49

Virometix Closes Financing Round

Please login or
register to use the
awards follow feature
29.12.2015 16:41

Virometix closes oversubscribed financing round

Please login or
register to use the
awards follow feature
28.11.2014 12:37

Virometix closes extension financing round

Please login or
register to use the
awards follow feature
25.06.2012 15:46

Gewinner des Awards der W. A. de Vigier Stiftung: Virometix

Please login or
register to use the
awards follow feature
21.06.2012 10:53

Sieben Mal 100 000 Franken für Gründer

Please login or
register to use the
awards follow feature
20.06.2012 17:22

CTI Start-up Label for Numab, Qvanteq, SwissTV and Virometix

Please login or
register to use the
awards follow feature
Virometix

Founded
2009

Kanton
ZH

Homepage

rss